Objectives

After participating in this educational activity, attendees should be able to:
1. List indications for the 4 approved therapies for Sickle Cell Disease (SCD).
2. Contrast Acute versus Chronic Pain Management.
3. Describe novel therapies in SCD.

Faculty

Deepa Manwani, MD
Professor of Pediatrics
Albert Einstein College of Medicine

Faculty Disclosure
Shannon Kay, PH.D., BCBA-D is a stock shareholder in Allergan, Pfizer, Glaxosmithklein, Merck, Gilead.

Session date: 
Tuesday, April 30, 2019 - 8:00am to 9:00am
Location: 
Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 BCIPE Instructional Hours
  • 1.00 APA Psychologists American Psychological Association
    Baystate Health is approved by the American Psychological Association to sponsor continuing education for psychologists. Baystate Health maintains responsibility for this program and its content.

Please login or register to take this course.